Mini-symposium
Synergistic Platforms for Next-Generation Drug Discovery: Integrating iPSC-Based Assays, High-Throughput Screening, MEA, and Organelle Analysis
Event co-organized by Axxam, FUJIFILM Cellular Dynamics, Axion BioSystems and ORIA Bioscience
Featuring guest speakers from prominent biopharma companies and innovative academic researchers
Date: 8 September 2026
Time: 10.00 AM – 4.00 PM
Location:
Switzerland Innovation Park Basel Area AG
Hegenheimermattweg 167A
4123 Allschwil, Switzerland
Scientific seminar and networking
FUJIFILM Cellular Dynamics, Axion BioSystems, ORIA Bioscience and Axxam are pleased to present a seminar showcasing the integration of key components of clinically translatable early drug discovery.
Successfully translating early drug discovery efforts to the clinic requires:
- Access to patient-based and disease-relevant material and models
- High-throughput functional screening
- An ability to interrogate and integrate across model systems and modalities to generate actionable clinically relevant data
This seminar will showcase advancements and case-studies on these topics with an emphasis on cardiovascular and neurodegeneration discovery efforts.
Attendees will enjoy a light lunch and refreshments and have an excellent opportunity for networking with colleagues, peers, and subject-matter experts as they learn about the intersection of high-throughput functional screening, clinically relevant disease models, and successful integration into drug discovery campaigns.
Agenda coming soon. Stay tuned! We'll be publishing the full seminar agenda shortly.
Speaker lineup coming soon. Stay tuned! We'll be announcing our confirmed speakers shortly.
Event organizers
Axxam is a leading provider of integrated discovery services across the life sciences industry. Axxam supports pharmaceutical and biotechnology companies, start-ups, patient foundations, and academic institutions throughout the drug discovery journey, from AI-enabled target identification and wet-lab target validation to hit identification and hit-to-lead optimization, regardless of therapeutic area or target class. Its services include assay development, high-throughput screening using either Axxam’s proprietary synthetic and natural compound collections or client libraries, hit validation, hit-to-lead, and compound management. The same science-driven approach is also applied to the discovery of new bioactive compounds for crop protection, animal health, food and beverage, pet food, cosmetics, and fragrance applications.
FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human cells used in drug discovery, toxicity testing, stem cell banking, and cell therapy development. The Company partners with innovators from around the world to combine biologically relevant human cells with the newest technologies to drive advancements in medicine. FCDI’s technology enables the creation of induced pluripotent stem cells (iPSCs) from anyone and followed by the powerful capability to develop into any cell type in the human body. Our proprietary manufacturing system produces billions of cells daily, resulting in inventoried and donor-specific iCell® Products in the quantity, quality, purity, and reproducibility required for drug and cell therapy development. FCDI is based in Madison, Wisconsin.
For more information, please visit www.fujifilmcdi.com
Axion BioSystems empowers scientists to reach new heights of discovery with high-quality, user-friendly lab tools that deliver powerful live-cell analysis for biomedical research applications. From investigating disease mechanisms in neurology and cardiology to developing lifesaving immunotherapies and antivirals, Axion’s award-winning products are designed to accelerate scientific breakthroughs and transform therapeutic development from discovery to manufacturing. Engineered for continuous, noninvasive monitoring of 2D and 3D in vitro cell models from the benchtop or incubator, Axion’s state-of-the-art Maestro, Omni, and Lux systems are indispensable tools in academic, biotechnology, and pharmaceutical labs worldwide.
For more information, please visit www.axionbiosystems.com
ORIA Bioscience™ provides, for the first time, isolated high-quality organelles at scale, in preparations compatible with high-throughput screening (HTS) drug discovery platforms. We empower and accelerate therapeutic discoveries, allowing pharmaceutical companies to conduct their processes directly on organelles (lysosomes, mitochondria, endoplasmic reticulum). Our products, LYSO-Prep™ and MITO-Prep™, bring together industrial scale, physiological fidelity, and true ready-to-use simplicity, shifting drug discovery from a cell-based vision to an organelle-based reality. Our organelles are customizable across all therapeutic areas and enhance assay results in terms of relevance, precision, and reproducibility. Fully functional and storable, extracted and sorted by our patented microfluidic process, our organelles pave the way for more accurate Hit-to-Lead and Lead Optimization testing, delivering the efficacy and batch-to-batch reproducibility that successful drug discovery decisions demand.
For more information, please visit www.oriabs.com